Mylan/3M launch new asthma inhaler; Another abuse-deterrent opioid being developed;

> Mylan ($MYL) announced the launch of the first bioequivalent alternative to GlaxoSmithKline's ($GSK) Seretide Evohaler in the United Kingdom, dubbed Sirdupla. The pressurized metered-dose inhaler to treat asthma will be manufactured by 3M Drug Delivery Systems. More

> Egalet said its investigational opioid passed tests of abuse deterrence. It demonstrated high resistance to crushing and grinding with 11 household tools, and heating the tablet did not alter its resistance to physical manipulation attempts, the company says. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.